Naqeeb Ansari - EnteroMedics Senior Vice President - Sales
President
Mr. Naqeeb A. Ansari is the Senior Vice President Sales of the Company. Naqeeb A. Ansari has served as our Senior Vice President of Sales since January 6, 2016. Mr. Ansari has over 20 years of experience in the medical device industry, having held various senior sales positions at Stryker Corporationrationration, DePuy, Medtronic, Inc., Lanx, Inc. and Globus Medical Inc. Prior to joining the Company he spent two years as the owner of an independent distributor solely selling Biomet products. Prior to this, he served as Senior Vice President of Sales at Lanx, Inc. from 2010 to 2013. since 2016.
| Age | 55 |
| Tenure | 8 years |
| Phone | 651-634-3003 |
| Web | http://www.enteromedics.com |
EnteroMedics Management Efficiency
The company has return on total asset (ROA) of (48.42) % which means that it has lost $48.42 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (146.32) %, meaning that it created substantial loss on money invested by shareholders. EnteroMedics' management efficiency ratios could be used to measure how well EnteroMedics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jan Craps | Anheuser Busch Inbev | 47 | |
| Deirdre Mahlan | Diageo PLC ADR | 56 | |
| Paul Whittleston | Ecovyst | 49 | |
| John Kennedy | Diageo PLC ADR | 59 | |
| Ewan Andrew | Diageo PLC ADR | N/A | |
| Roberto Inchaustegui | Ecolab Inc | 63 | |
| Alex Blanco | Ecolab Inc | 57 | |
| Timothy Mulhere | Ecolab Inc | 61 | |
| Steve Pittari | Park Electrochemical | N/A | |
| Paul Farabaugh | Park Electrochemical | 56 | |
| Ricardo Tadeu | Anheuser Busch Inbev | 48 | |
| Stephen Taylor | Ecolab Inc | 54 | |
| Jean Jereissati | Anheuser Busch Inbev | 46 | |
| Nicholas Blazquez | Diageo PLC ADR | 52 | |
| Larry Berger | Ecolab Inc | 63 | |
| Bryan Hughes | Ecolab Inc | 46 | |
| Angela Busch | Ecolab Inc | 57 | |
| Constantine Petropoulos | Park Electrochemical | 41 | |
| Debra Crew | Diageo PLC ADR | 54 | |
| Benjamin Shore | Park Electrochemical | 31 | |
| Carlos Lisboa | Anheuser Busch Inbev | 55 | |
Management Performance
| Return On Equity | -146.32 | |||
| Return On Asset | -48.42 |
EnteroMedics Leadership Team
Elected by the shareholders, the EnteroMedics' board of directors comprises two types of representatives: EnteroMedics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EnteroMedics. The board's role is to monitor EnteroMedics' management team and ensure that shareholders' interests are well served. EnteroMedics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EnteroMedics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jon Tremmel, Consultant To The CEO and Director | ||
| Peter Delange, Senior Vice President - Operations and Business Development | ||
| Scott Youngstrom, CFO, Chief Compliance Officer | ||
| Dan Gladney, CEO and President and Director | ||
| Nicholas Teti, Independent Director | ||
| Carl Goldfischer, Independent Director | ||
| Catherine Friedman, Independent Director | ||
| Michael Mashaal, Director | ||
| Lori McDougal, Director | ||
| Gary Blackford, Director | ||
| Nick Ansari, Senior Vice President - Sales | ||
| Scott Shikora, Executive Vice President - Medical Affairs and Chief Medical Officer | ||
| Anthony Jansz, Director | ||
| Adrianus Donders, Sr. VP of Research and Advanced Devel. | ||
| Katherine Tweden, Co-Founder and VP of Clinical and Regulatory | ||
| Mark Knudson, Founder and Executive Chairman | ||
| Gregory Lea, CFO, Principal Accounting Officer, Chief Compliance Officer and Secretary | ||
| Paul Hickey, Senior Vice President - Marketing and Reimbursement | ||
| Bobby Griffin, Independent Director | ||
| Tonya Dowd, Vice President - Reimbursement | ||
| Naqeeb Ansari, Senior Vice President - Sales |
EnteroMedics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EnteroMedics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -146.32 | |||
| Return On Asset | -48.42 | |||
| Current Valuation | 5.39 M | |||
| Shares Outstanding | 14.57 M | |||
| Shares Owned By Insiders | 6.79 % | |||
| Shares Owned By Institutions | 2.64 % | |||
| Number Of Shares Shorted | 1.13 M | |||
| Price To Earning | (0.32) X | |||
| Price To Book | 0.45 X | |||
| Price To Sales | 52.22 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards EnteroMedics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, EnteroMedics' short interest history, or implied volatility extrapolated from EnteroMedics options trading.
Pair Trading with EnteroMedics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EnteroMedics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnteroMedics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to United States could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United States when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United States - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United States Steel to buy it.
The correlation of United States is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United States moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United States Steel moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United States can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in EnteroMedics Stock
If you are still planning to invest in EnteroMedics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EnteroMedics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |